RxDoctor Payments Data

Elizabeth Hughes, PA

Medical · Portland, ORNPI 1629479282

Payments from drug & device makers

$629in general payments, 2019–2025

Across 29 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$140
  • Davol Inc.$114
  • E.r. Squibb & Sons, L.L.C.$68
  • Novo Nordisk$56
  • Revance Therapeutics, Inc.$45
  • Lilly USA, LLC$34
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$629 in reported general payments places this provider in the 65th percentile of 364 medical providers in Oregon.

See all medical providers in Oregon

Medicare billing

Part B allowed, 2024
$14,828
Medicare patients
80
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$70,099
EliquisApixaban52$43,187
MounjaroTirzepatide40$39,167
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$35,373
JardianceEmpagliflozin26$21,707
MyrbetriqMirabegron14$13,747
FarxigaDapagliflozin Propanediol12$10,564
Spiriva RespimatTiotropium Bromide11$5,821
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$5,470
Incruse ElliptaUmeclidinium Bromide15$5,422
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,291
ArexvyRsvpref3 Antigen/As01e/Pf12$3,771
Atorvastatin Calcium269$3,188
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$2,877
Albuterol Sulfate HfaAlbuterol Sulfate84$2,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$56$70,09941 claims
GSKTrelegy Ellipta, Incruse Ellipta, Shingrix, Arexvy$11$48,85784 claims
Lilly USA, LLCMounjaro$34$39,16740 claims
Boehringer IngelheimJardiance, Spiriva Respimat$19$27,52937 claims
Astellas Pharma US IncMyrbetriq$20$13,74714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 364 medical providers in Oregon.

Other medical in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →